Document:

Exhibit 10.9

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT is entered
into as of May 22, 2015 and effective as of April 28, 2015 by and between FreeCast, Inc., a Florida corporation (the “Company”),
and Christopher M. Savine, an individual (the “Executive”).

 

RECITALS:

 

A.          The Company and
the Executive have previously entered into an Employment Agreement dated as of April 15, 2014 (the “Initial Agreement”),
and Amended and Restated as of June 10, 2014.

 

B.           Each of the Company and the Executive
desires to extend the Employment Agreement in accordance with the terms contained herein.

 

NOW, THEREFORE,
in consideration of the Recitals, and the respective covenants and agreements of each of the Company and the Executive contained
in this Agreement, each of the Company and the Executive agrees as follows:

 

ARTICLE I

Certain Definitions

 

The following terms shall have the following
respective meanings when utilized in this Agreement:

 

“Agreement” shall have the meaning set forth in
the Recital B.

 

“Affiliate”
means, with respect to any specified Person, any other Person which, directly or indirectly, controls, or is controlled by or is
under common control with, such specified Person. For purposes of this definition, the concept of “control,” when used
with respect to any specified Person, signifies the possession of the power to direct the management and policies of such specified
Person, directly or indirectly, whether through the ownership of voting securities or partnership or other equity or ownership
interests, by contract or otherwise.

 

“Cause” means any of the following:

 

(a)          any action by the Executive or any
failure to act by the Executive which constitutes fraud, embezzlement, misappropriation, dishonesty or breach of trust;

 

     

     

    

 

(b)         any action by the Executive which constitutes
assault or any other act of violence;

 

(c)          any action by the Executive which constitutes
sexual harassment or discrimination on the basis of race, ethnicity, religion, gender or sexual preference;

 

(d)          the Executive’s conviction or
plea of guilty or nob o contendre to any felony whatsoever or to any misdemeanor if the sentence therefor includes incarceration;

 

(e)          the Executive’s
attendance at work in a state of intoxication or being found with any drug or substance possession which would constitute a criminal
offense of any kind;

 

the Executive’s
carrying out any activity or making any public statement which prejudices or diminishes the good name, reputation or standing of
the Company or any its Affiliates or would cause any of them to be subjected to public contempt or ridicule;

 

(g)         any action or failure to act by the
Executive which constitutes a violation of law, including without limitation any violation of any federal or state securities laws;

 

(h)         any breach or violation by the Executive
of any or all of his material covenants or agreements set forth in this Agreement;

 

(i)           any failure or refusal by the Executive
to perform any or all of his material duties and responsibilities as an employee of the Company; or

 

(j)           gross negligence by the Executive
in the performance of any or all of his material duties and responsibilities as an employee of the Company.

 

“Certificate”
shall have the meaning set forth in Section 5.2(a).

 

“Common Stock”
shall have the meaning set forth in Section 5.1.

 

“Company”
means FreeCast, Inc., a Florida corporation.

 

“Confidential
Information” shall have the meaning set forth in Section 9.1(a).

 

“Disability”
means any mental or physical illness, condition, disability or incapacity which prevents the Executive from reasonably discharging
his duties and responsibilities as an officer of the Company. If any disagreement or dispute shall arise between the Company and
the Executive as to whether the Executive suffers from any Disability, then, in such event, the Executive shall submit to the physical
or mental examination of a licensed physician chosen solely by the Company, and such physician shall determine whether the Executive
suffers from any Disability. In the absence of fraud or bad faith, the determination of such physician shall be final and binding
upon the Company and the Executive. The entire cost of such examination shall be paid for solely by the Company.

 

    	2

     

    

 

“Escrow Agreement”
shall have the meaning set forth in Section 5.2(a).

 

“Executive”
means Christopher M. Savine, an individual.

 

“Initial Agreement”
shall have the meaning set forth in Recital A.

 

“Law Firm”
shall have the meaning set forth in Section 5.2(a).

 

“Person” means any individual,
person, sole proprietorship, company, corporation, partnership, limited liability company, joint venture, trust, association or
other entity, or any combination of the foregoing.

 

“Policies”
shall have the meaning set forth in Section 8.5.

 

“Restrictive
Covenants” shall have the meaning set forth in Section 8.2.

 

“Salary”
shall have the meaning set forth in Section 4.1.

 

“Section 83(b)
Election” shall have the meaning set forth in Section 5.2(e).

 

“Shares”
shall have the meaning set forth in Section 5.2(a).

 

“Tax Related
Items” shall have the meaning set forth in Section 5.2(d).

 

“Term”
shall have the meaning set forth in Section 3.1.

 

“Termination Date” means a
specific date not less than fifteen nor more than forty-five days from and after the date of any Termination Notice upon which
the Executive’s employment by the Company shall terminate.

 

“Termination Notice” shall
mean a written notice which sets forth (a) the specific provision of this Agreement relied upon to terminate the Executive’s
employment and (b) a Termination Date.

 

“Territory”
means the United States of America and its territories and possessions.

 

“Trade Secrets”
shall have the meaning set forth in Section 9.1(b).

 

    	3

     

    

 

ARTICLE II

Employment

 

2.1         Employment. The Company
employs the Executive and the Executive accepts such employment. Subject to the direction of the Board of Directors and the Chief
Executive Officer, the Executive shall serve as the Chief Financial Officer of the Company. The Executive shall have such responsibilities,
perform such duties and exercise such power and authority as may from time to time be delegated to him by the Board of Directors
or the Chief Executive Officer or are inherent in, or incident to, such office. The Executive shall devote substantially all of
his business time and attention and his best efforts to the diligent, professional and ethical performance of his duties as an
employee of the Company.

 

2.2         Chance in Position. If
the Executive’s position with the Company shall change for any reason, then this Agreement shall terminate, and the provisions
of Section 7.4 shall apply.

 

ARTICLE III

Term

 

3.1         Term.
The term of the Executive’s employment by the Company shall be for a period of one year, commencing on April 28, 2015
and continuing through April 27, 2016 (the “Term”). Subsequent to April 27, 2016, the Term shall be automatically
extended on a month-to-month basis. Notwithstanding the provisions of the immediately preceding sentences, the
Executive’s employment by the Company may be terminated prior to the expiration of the initial Term or any extension
thereof in accordance with the provisions of Article VII below.

 

ARTICLE IV

Salary

 

4.1         Salary. In full payment
for the obligations to be performed by the Executive during the term of this Agreement, effective as of April 28, 2015, the Company
shall pay to the Executive a salary (subject to applicable payroll and/or other taxes required by law to be withheld) equal to
One Hundred Fifty Thousand Dollars ($150,000.00) for the year ending April 27, 2016 (the “Salary”), and Two Hundred
Fifty Thousand Dollars ($250,000.00) per annum thereafter until a new extension is executed between the parties.

 

4.2         Payment of Salary. The
Salary shall be paid to the Executive in installments from time to time on the same dates payments of salary are generally made
to all senior management employees of the Company.

 

    	4

     

    

 

ARTICLE V

Incentives

 

5.1         Warrants. In order to
induce the Executive to enter into the Initial Agreement and perform his obligations thereunder and hereunder and the payment to
the Company of Fifty Dollars ($50.00), the Executive has executed and delivered to the Company a subscription agreement and the
Company has previously issued to the Executive warrants to purchase an aggregate of Two Hundred Seventy-Four Thousand Thirty-Three
(274,033) shares of its common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of Twenty-Five
Cents ($0.25) per share. The aforementioned warrants shall vest upon the execution of this agreement.

 

5.2         Shares.

 

(a)          In addition to
the aforementioned Salary and Warrants, the Company shall cause the issuance in the name of the Executive of a stock certificate
(the “Certificate”) representing Six Hundred Seventy-five Thousand (675,000) shares of Common Stock (the “Shares”)
for and in consideration of services rendered, or to be rendered, by the Executive to the Company for the year ending April 27,
2016, earned ratably over the employment year. The Company shall deliver the Certificate to the law firm of Winderweedle, Haines,
Ward & Woodman, P.A. (the “Law Firm”) to be held in escrow in accordance with the provisions of that certain
Escrow Agreement of even date herewith (the “Escrow Agreement”). The Executive shall execute and deliver a subscription
agreement to the Company.

 

(b)          The Executive
acknowledges that that, prior to his receipt of the Certificate, it is likely that the Company will declare or authorize a stock
split or dividend, reverse stock split, combination, exchange of shares, recapitalization, reclassification (including any consolidation
or merger), sale or acquisition of property or stock, reorganization or liquidation, or conversion of outstanding shares of Common
Stock into the same or a different number of shares of the same or another class or classes of stock of the Company.

 

(c)          The Executive
shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to the Executive,
the amount of any required withholding taxes in respect of the shares of Common Stock issued pursuant to Section 5.2(a) and to
take all such other action as the Company deems necessary to satisfy all obligations for the payment of such withholding taxes.
The Company may permit the Executive to satisfy any federal, state or local tax withholding obligation by any of the following
means, or by a combination of such means:

 

(i)           tendering a cash payment;

 

    	5

     

    

 

(ii)          authorizing
the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable or deliverable to the Executive
in accordance with the provisions of the Escrow Agreement; provided,
however, that no shares of Common Stock shall be withheld with a value exceeding the minimum amount of tax required
to be withheld by law; or

 

(iii)        delivering to the Company previously
owned and unencumbered shares of Common Stock.

 

(d)          Notwithstanding
any action the Company takes with respect to any or all income tax, social security, payroll tax, or other tax-related withholding
(collectively, the “Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Executive’s
sole responsibility and the Company (i) makes no representation or undertaking regarding the treatment of any Tax-Related Items
in connection with the issuance or delivery of the Shares pursuant to Section 5.2(a) or the subsequent sale of any such Shares
and (ii) does not commit to structure any transaction to reduce or eliminate the Executive’s liability for Tax-Related Items.

 

(e)          The Executive may
make an election under Section 83(b) of the Internal Revenue Code of 1986 (a “Section 83(b) Election”) with respect
to the Shares to be issued pursuant to Section 5.2(a). Any such election must be made within thirty days after the date of this
Agreement. If the Executive elects to make a Section 83(b) Election, then the Executive shall provide the Company with a copy of
an executed version and satisfactory evidence of the filing of the executed Section 83(b) Election with the Internal Revenue Service.
The Executive shall have full responsibility for ensuring that the Section 83(b) Election is actually and timely filed with the
Internal Revenue Service and for all tax consequences resulting from the Section 83(b) Election.

 

5.3         Bonus.
The Executive shall have the opportunity to earn a discretionary bonus on an annual basis as may be determined in the sole discretion
of the Board of Directors of the Company. Any such bonus shall be subject to applicable payroll and/or other taxes required by
law to be withheld.

 

ARTICLE VI

Certain Fringe Benefits

 

6.1        Generally.
The Executive may receive such benefits and participate in such benefit plans as are generally provided from time to time by
the Company to its senior management employees; provided,
however, that nothing contained in this Section 6.1 shall be construed to obligate the Company to provide any
specific benefits to its respective senior management employees generally or to the Executive specifically.

 

    	6

     

    

 

6.2         Vacations. The Executive
shall be entitled to four weeks’ vacation time on an annual basis in accordance with such policies as are from time to time
adopted by the Company’s Board of Directors with respect to its senior management employees.

 

6.3         Business, Travel and Entertainment
Expenses. Within a reasonable time after the submission of appropriate receipts and other evidence by the Executive, the
Company shall pay, or reimburse the Executive for, all reasonable business, travel and entertainment expenses incurred by the Executive
in connection with the performance of his duties and responsibilities on behalf of the Company.

 

ARTICLE V11

Termination of Employment

 

7.1         Termination
of Employment.

 

(a)          Notwithstanding the provisions of Article
III above, the employment of the Executive (i) shall automatically terminate upon the death of the Executive pursuant to the provisions
of Section 7.2, (ii) may be terminated at any time by the Company pursuant to the provisions of Sections 7.3 or 7.4 and (iii) may
be terminated at any time by the Executive pursuant to the provisions of Section 7.5.

 

(b)          If the Company
shall desire to terminate the Executive’s employment by the Company pursuant to any of the provisions of Sections 7.3 or
7.4 of this Agreement, then, in such event, the Company shall provide a Termination Notice to the Executive.

 

(c)          If the Executive
shall desire to terminate his employment by the Company pursuant to the provisions of Sections 7.5 of this Agreement, then, in
such event, the Executive shall provide a Termination Notice to the Company.

 

(d)          If the Executive’s employment by the Company shall be terminated pursuant to any of the provisions of this Article VII,
then the Company shall be discharged from all of its obligations to the Executive under this Agreement upon the payment to the
Executive of the amount set forth in the Section of this Article VII pursuant to which such
termination of employment shall occur. The Executive’s sole and exclusive remedy for the termination of his employment by
the Company prior to the expiration of the Term, regardless of whether such termination shall be initiated by the Company or the
Executive, shall be the payment by the Company to the Executive of the amount set forth in the Section of this Article VII pursuant
to which such termination shall occur. 

 

    	7

     

    

 

7.2         Death
of Executive. If during the Term the Executive shall die, then the employment of the
Executive by the Company shall automatically terminate on the date of the Executive’s death. In such event, the Company shall
be obligated to pay to the Executive’s estate or as otherwise directed by the Executive’s personal representative or
executor, the Executive’s Salary and earned Warrants and Shares (subject to applicable payroll and/or other taxes required
by law to be withheld) through the date of the Executive’s death. 

 

7.3         Disability
of Executive. If during the Term the Executive shall suffer any Disability,
then the Company may terminate the Executive’s employment. In such event, the Company shall pay to the Executive or as otherwise
directed by the Executive’s legal representative his Salary and earned Warrants and Shares (subject to applicable payroll
and/or taxes required by law to be withheld) through the Termination Date set forth in the Termination Notice.

 

7.4         Termination
of Employment by Company.

 

(a)          The Company may
terminate the Executive’s employment at any time with Cause. In such event, the Company shall continue to pay to the Executive
in the ordinary and normal course of its business his Salary and earned Warrants and Shares (subject to applicable payroll and/or
other taxes required by law to be withheld) through the Termination Date set forth in the Termination Notice.

 

(b)          The Company may
terminate the Executive’s employment at any time without Cause. In such event, (i) the Company shall continue to pay to the
Executive in the ordinary and normal course of its business his Salary (subject to applicable payroll and/or other taxes required
by law to be withheld) through the Termination Date set forth in the Termination Notice and (ii) the Company shall continue to
pay to the Executive a salary at the rate of Two Hundred Thousand Dollars ($250,000.00) per annum (subject to applicable payroll
and/or other taxes required by law to be withheld) for a period of six months subsequent to the Termination Date set forth in the
Termination Notice and (iii) all Warrants and Shares as defined in this Agreement shall vest on the Termination Date.

 

7.5          Termination
of Employment by Executive. The Executive may terminate his employment at any time.
In such event, the Company shall continue to pay to the Executive in the ordinary and normal course of its business his Salary
and earned Warrants and Shares (subject to applicable payroll and/or other taxes required by law to be withheld) through the Termination
Date set forth in the Termination Notice. 

 

    	8

     

    

 

ARTICLE VIII

Certain Covenants of the Executive

 

8.1        Certain Restrictive Covenants.
The Executive covenants and agrees with the Company and each Affiliate of the Company as follows:

 

(a)          He shall not at
any time, directly or indirectly, for himself or for any other Person, approach, counsel, solicit, induce or attempt to approach,
counsel, solicit or induce any Person employed or engaged by the Company or any Affiliate of the Company, whether such Person is
a full-time employee, part-time employee or independent contractor, to terminate his, her or its employment or independent contractor
relationship with the Company or any Affiliate of the Company.

 

(b)          He shall not
at any time, directly or indirectly, for himself or for any other Person employ, attempt to employ or enter into any contractual
arrangement for employment with, engage, attempt to engage or enter into any contractual arrangement for the engagement of, any
employee or former employee or independent contractor or former independent contractor of the Company or any Affiliate of the Company,
unless such former employee or independent contractor shall not have been employed or engaged by the Company or any Affiliate of
the Company for a period of at least one year.

 

(c)          He shall not,
while he is employed by the Company and for a period of one year from and after the date that his employment by the Company ceases
or terminates for any reason, directly or indirectly, for himself or for any other Person:

 

(i)          acquire or own
in any manner any interest in, or loan any amount to, any Person which competes in any manner with the Company or any Affiliate
of the Company anywhere in the Territory;

 

(ii)         be employed
by or serve as an employee, agent, officer, director or manager of, or as a consultant to, or as an independent contractor or salesperson
for, any Person which competes in any manner with the Company or any Affiliate of the Company in the Territory;

 

(iii)        solicit, attempt
to solicit, market, sell or provide, or attempt to market, sell or provide, any goods or services to any customer of the Company
or any Affiliate of the Company, other than on behalf of the Company or an Affiliate of the Company or unless any such customer
has not been a customer of the Company or any Affiliate of the Company for a period of at least one year;

 

(iv)        procure goods
or services from any supplier or vendor of the Company or any Affiliate of the Company, other than on behalf of the Company or
an Affiliate of the Company or unless any such supplier or vendor has not been a supplier or vendor to the Company or any Affiliate
of the Company for a period of at least one year;

 

    	9

     

    

 

(v)         compete in any manner with the Company
or any of its Affiliates in the Territory; or

 

(vi)        interfere with,
disrupt, or attempt to interfere with or disrupt, any existing relationship, contractual or otherwise, between the Company or any
Affiliate of the Company on the one hand, and any of the respective employees, independent contractors, customers, suppliers, vendors
or other Persons with which any of the Company or its Affiliates has business relations or deals with on the other.

 

The foregoing provisions
of this Section 8.1(c) shall not prevent the Executive from acquiring and owning not more than one percent of the equity securities
of any Person whose securities are listed for trading on a national securities exchange or are regularly traded in the over-the-counter
securities market.

 

8.2         Independent
Agreements. The restrictive covenants set forth in Section 8.1 above (collectively, the “Restrictive Covenants”)
shall be construed as agreements independent of any other provision contained in this Agreement, and the existence of any claim
or cause of action, whether predicated upon this Agreement or otherwise, against the Company or any of its Affiliates shall not
constitute a defense to the enforcement by the Company or any of its Affiliates of any of the Restrictive Covenants. The Executive
acknowledges that the Company has fully performed all obligations entitling it to the benefits of the Restrictive Covenants, and
that the Restrictive Covenants, therefore, are not executory or otherwise subject to rejection under the Bankruptcy Code of 1978.

 

8.3         Reasonable Restraint. Each
of the Company and the Executive acknowledges that each of the Restrictive Covenants is a reasonable and necessary restraint of
trade and does not violate any applicable laws, rules or regulations, including without limitation the Sherman Antitrust Act, the
Florida Antitrust Act or the common law Each of the Company and the Executive acknowledges that the Company conducts its business
activities on a worldwide basis and throughout the Territory. Each of the Company and the Executive acknowledges that each of the
Restrictive Covenants is supported by valid and legitimate business interests, including without limitation the need to protect
the Confidential Information and Trade Secrets (as such terms are hereinafter defined) of the Company and its Affiliates, and the
need to protect the substantial relationships of the Company and its Affiliates with their respective employees and independent
contractors, current and prospective customers, and current and prospective vendors, and that the period of restriction set forth
in Section 8.1(c) above is essential to the full protection of each of such valid and legitimate business interests.

 

8.4         Severability.
Each of the Company and the Executive agrees that each of the Restrictive Covenants is reasonable and proper with respect to duration,
geographical scope, and lines of business. If all or any portion of any of the Restrictive Covenants is held by a court of competent
jurisdiction to be unreasonable, arbitrary or against public policy for any reason, then all or such portion of such Restrictive
Covenants shall be considered divisible as to duration, geographical scope or lines of business, or may be otherwise narrowed so
as to be enforceable. If a court of competent jurisdiction shall determine that a time period, a geographical area or a specified
line of business is unreasonable, arbitrary or against public policy for any reason, then a shorter period, a smaller geographical
area or a narrower line of business, as shall be determined by such court to be reasonable, non-arbitrary and not against public
policy, may be enforced against the Executive by the Company.

 

    	10

     

    

 

8.5         Certain Policies. The Executive
acknowledges that (a) he has been provided with a copy of the Company’s Policies Regarding Electronic Information Systems,
Electronic Mail, Internet and Telephone and Other Communications (the “Policies”), (b) he has read the Policies, (c)
he has had an opportunity ask questions of and to seek information regarding the Policies, (d) he understands the Policies and
(e) he accepts, consents to and agrees to abide by the Policies.

 

8.6         Assignment of Works. The
Executive assigns to the Company or its assigns all of the Executive’s right, title and interest in and to all developments,
inventions and ideas made, conceived or reduced to practice solely or jointly by the Executive while engaging in activities within
the scope of his employment by the Company, regardless of whether any of such developments, inventions and ideas qualify as intellectual
property or were conceived or developed during business hours. The Executive acknowledges and agrees that all original works of
authorship that are made with the scope of his employment by the Company and which can be legally protected are “works for
hire” under applicable law. The Executive shall notify the Company of all developments, inventions and ideas and to take
all actions necessary to enable the Company to seek legal protection for them.

 

ARTICLE IX

Confidential Information and Trade
Secrets

 

9.1         Certain Definitions.

 

(a)          “Confidential
Information” includes information which (a) has been or is developed or is otherwise owned by the Company or any of its Affiliates,
whether developed by the Company or an Affiliate of the Company or by any other Person, (b) is not readily available to the public
and not generally ascertainable by proper means by the public, (c) if disclosed to the public, would be harmful to the interests
of the Company or any Affiliate of the Company, (d) has limited disclosure within the Company or any Affiliate of the Company,
or (e) is treated or designated by the Company or any Affiliate of the Company as being confidential. Confidential Information
may consist of technical information, including without limitation inventions, formulas, compilations, computer programs, software,
databases, methods, purchasing techniques and processes, sales techniques and processes, market data and pricing and discounting
practices, as well as business information relating to the financial condition, financial arrangements, business plans or strategies
(such as new products and services and plans for sales, marketing, purchasing, distribution, services or promotions), employee
training materials, sales manuals, customer needs, contacts, accounts and the like, vendor or supplier lists, vendor or supplier
needs, contacts, accounts and the like, personnel, payroll and financial data and records, and any and all data, information, plans,
processes, procedures, methods and records of any kind or nature whatsoever, regardless of the form of storage medium and wherever
located, related in any manner to the Company or any Affiliate of the Company or their respective businesses, operations or affairs
or their respective members, managers, directors, officers, employees, agents or independent contractors.

 

    	11

     

    

 

(b)         “Trade Secrets”
include Confidential Information which is sufficiently secret to derive actual or potential economic value to the Company or an
Affiliate of the Company from not being generally known to, and not being readily ascertainable by, the competitors of the Company
or an Affiliate of the Company and other Persons (including without limitation the vendors, suppliers and customers of the Company
or any Affiliate of the Company), which information gives, or has the potential of giving, the Company or any Affiliate of the
Company an advantage over the competitors of the Company or any Affiliate of the Company or other Persons (including without limitation
the vendors, suppliers and customers of the Company or any Affiliate of the Company) which can obtain economic value from the disclosure
or use of the information and which information the Company or any Affiliate of the Company has taken, and will continue to take,
reasonable steps to maintain as secret or confidential vis-a-vis its current and potential competitors and other Persons (including
without limitation the Company’s vendors, suppliers and customers).

 

9.2         Ownership
of Confidential Information and Trade Secrets. The Executive acknowledges that, in
the course of his relationship with the Company, he has received, used, had access to and became familiar with, or in the future
will receive, use, have access to and become familiar with, the Confidential Information and the Trade Secrets which are owned
by the Company or by an Affiliate of the Company or which are or will be otherwise used in connection with the current or future
business of the Company or an Affiliate of the Company. The Executive acknowledges and agrees that all such Confidential Information
and Trade Secrets are and shall remain the sole and exclusive property of the Company or an Affiliate of the Company, as the case
may be, and that the covenants set forth in Section 9.3 below are fair and reasonable. 

 

9.3         Non-Disclosure. The
Executive shall not, directly or indirectly, at any time disclose to any Person, or take or use for the purposes of any Person,
other than the Company or its Affiliates, any Confidential Information or Trade Secrets. The Executive shall not, directly or indirectly,
at any time copy or place any Confidential Information or Trade Secrets on to any personal computer or other data collection or
storage device that is not owned by the Company or an Affiliate of the Company. The obligations of the Executive set forth in this
Section 9.3 apply to, and are intended to prevent, the direct or indirect disclosure of any Confidential Information or Trade Secrets
to Persons where such disclosure of the Confidential Information or the Trade Secrets would reasonably be considered to be useful
to the competitors of the Company or any of its Affiliates or to any other Person to become a competitor based, in whole or in
part, on such Confidential Information or Trade Secrets. Immediately upon the termination of the Executive’s employment by
the Company for any reason, the Executive shall deliver to the Company all Confidential Information and Trade Secrets and all Company
property then in his possession.

 

    	12

     

    

 

9.4         Independent Agreements. The covenants set forth in
Section 9.3 above shall be construed as an agreement independent of any other provision contained
in this Agreement, and the existence of any claim or cause of action, whether predicated upon this Agreement or otherwise, against
the Company or any of its Affiliates shall not constitute a defense to the enforcement by the Company or any of its Affiliates
of any of such covenants. The Executive acknowledges that the Company has fully performed all obligations entitling it to the benefit
of the covenants set forth in Section 9.3 above, and that such covenants, therefore, are not executory or otherwise subject to
rejection under the Bankruptcy Code of 1978. 

 

ARTICLE
X

Remedies; Survival

 

10.1      Injunction;
Specific Performance. It is recognized and acknowledged by each of the parties that a breach or violation by the Executive
of any or all or the provisions contained in this Agreement will cause irreparable harm and damage to the Company and/or its Affiliates
in a monetary amount which would be virtually impossible to ascertain. As a result, each of the parties recognizes and acknowledges
that the Company and/or its Affiliates shall be entitled to the remedies of injunction and/or specific performance from any court
of competent jurisdiction enjoining and restraining any breach or violation by the Executive of any or all of the provisions contained
herein and/or requiring the specific performance of any or all of the provisions contained herein, and that such rights to injunction
and specific performance shall be cumulative and in addition to whatever other rights and remedies the Company and/or its Affiliates
may possess hereunder, at law and in equity.

 

10.2       Damages.
Except as otherwise provided in Article VII above, nothing contained in this Agreement shall be construed to prevent either
of the parties from seeking and recovering from the other party damages sustained by it, him or her as a result of the other party’s
breach or violation of any or all of the provisions of this Agreement.

 

10.3       Survival.
The provisions of Articles I, VIII, IX, X and XI of this Agreement shall survive indefinitely
the expiration of the Term or the termination of the Executive’s employment prior to the expiration of the Term. 

 

ARTICLE XI

Miscellaneous Provisions

 

11.1      Governing Law. This
Agreement shall be governed by, and shall be construed and interpreted in accordance with, the laws of the State of Florida, without
giving effect to the conflicts of laws provisions thereof.

 

    	13

     

    

 

11.2       Notices.
Any and all notices and other communications required or permitted to be given pursuant
to this Agreement shall be in writing and shall be deemed to have been duly given (a) when delivered by hand, (b) two days after
having been delivered to Federal Express, UPS or another recognized overnight courier or delivery service, (c) when delivered by
facsimile transmission, provided that an original copy of such transmission shall be sent by first class mail, postage prepaid,
or (d) five days after having been deposited into the United States mail, by registered or certified mail, return receipt requested,
postage prepaid, to the respective parties at their respective addresses or to their respective facsimile telephone numbers, as
follow: 

 

	If to the Company:	FreeCast, Inc.
	 	5850 TG Lee Boulevard
	 	Suite 310
	 	Orlando, Florida 32822
	 	Attention: Chief Executive Officer
	 	 
	If to the Executive:	Christopher M. Savine
	 	6000 Island Boulevard
	 	Unit 504
	 	Miami, Florida 33160

 

or to such other address or facsimile telephone
number as either party may from time to time give written notice of to the others pursuant to the foregoing provisions of this
Section 11.2. It is specifically understood and agreed by the parties that any notice or other communication given by telephone,
email, texting, tweeting or any other form or forms of communication not specifically permitted by subsections (a), (b), (c) or
(d) of this Section 11.2 shall not be deemed to be properly delivered for purposes of this Agreement and shall, therefore, be ineffective.

 

11.3       Entire
Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof
and supersedes all prior agreements, understandings, negotiations and arrangements, both oral and written, between
the parties with respect to such subject matter. Without limiting the generality of the immediately preceding sentence, the Initial
Agreement is superseded hereby and the Initial Agreement shall be of no further force or effect. This Agreement may not be amended
or modified in any manner, except by a written instrument executed by each of the parties.

 

11.4      Benefits;
Binding Effect. This Agreement shall be for the benefit of, and shall be binding upon, the parties hereto and their
respective heirs, personal representatives, executors, legal representatives, successors and assigns.

 

11.5       Jurisdiction and Venue; Service of Process; Waiver of Trial by Jury. If any dispute, controversy, suit, action or proceeding
shall arise between the parties, then such dispute, controversy, suit, action or proceeding may only be brought for resolution
in the United States District Court for the Middle District of Florida, Orlando Division, or in the Judicial Circuit Court in and
for Orange County, Florida. Each of the parties consents to the jurisdiction and venue of such courts, and agrees that it or he
shall not contest or challenge the jurisdiction or venue of such courts. Each of the parties agrees that service of any process,
summons, notice or document, by United States registered or certified mail, to its or her address set forth in or as provided herein
shall be effective service of process for any suit, action
or proceeding brought against it or him in any such court. In recognition of the fact that the issues which would arise under this
Agreement are of such a complex nature that they could not be properly tried before a jury, each of the parties waives trial by
jury. 

 

    	14

     

    

 

11.6      No Waivers.
The waiver by either party of a breach or violation of any provision of this Agreement by the other party shall not operate nor
be construed as a waiver of any subsequent breach or violation. The waiver by either party to exercise any right or remedy it or
he may possess shall not operate nor be construed as a bar to the exercise of such right or remedy by such party upon the occurrence
of any subsequent breach or violation.

 

11.7       Third Party
Beneficiaries. The Executive acknowledges and agrees that each and every present and future Affiliate of the Company shall
be entitled, as a third party beneficiary, to the rights and benefits of the representations, warranties, covenants and agreements
of the Executive set forth in this Agreement. Nothing contained in this Section 11.7 shall prohibit the modification of this Agreement
by the Company and the Executive in accordance with the provisions hereof.

 

11.8       Headings.
The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation
of any or all of the provisions hereof

 

11.9       Counterparts.
This Agreement may be executed in any number of counterparts and by the separate parties in separate counterparts, each of which
shall be deemed to constitute an original and all of which shall be deemed to constitute the one and the same instrument.

 

IN WITNESS WHEREOF, each of the
parties has executed and delivered this Agreement as of the date first written above.

 

	FreeCast, Inc.	 	 
	 	 	 
	By:	/s/ William A. Mobley	 	/s/ Christopher M. Savine
	 	William A. Mobley, Jr.,	 	Christopher M. Savine
	 	Chief Executive Officer	 	 

 

    	15Exhibit

Exhibit 4.15

DESCRIPTION OF COMMON STOCK REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

The following description (this “Description”) of the terms of the common stock of CVS Health Corporation (“CVS Health”) is a summary only and is qualified by reference to the relevant provisions of Delaware law and the Restated Certificate of Incorporation (the “Charter”) and the By-Laws (the “By-Laws”) of CVS Health. Copies of the Charter and the By-Laws are incorporated by reference as exhibits to the Annual Report on Form 10-K to which this Description is an exhibit.

Authorized Capital Stock
Under the Charter as of February 12, 2020, the authorized capital stock of CVS Health consisted of (i) 3,200,000,000 shares of common stock, par value of $0.01 per share (“common stock”), (ii) 120,619 shares of cumulative preferred stock, par value $0.01 per share (“preferred stock”), and (iii) 50,000,000 shares of preference stock, par value $1.00 per share (“preference stock”).

Common Stock
The holders of shares of common stock are entitled to one vote per share on all matters voted on by CVS Health stockholders, including elections of directors. Except as otherwise required by law, or by the provisions of the preferred stock or the preference stock, or provided in any resolution adopted by the CVS Health board of directors (the “board”) with respect to any subsequently created class or series of shares of CVS Health, the holders of the shares of common stock exclusively possess all voting power. The Charter precludes cumulative voting in the election of directors. The Charter provides for a majority vote standard for uncontested elections of directors, and a plurality of votes standard for contested elections of directors. Subject to any rights of any outstanding series of preferred stock or preference stock, (i) the holders of shares of common stock are entitled to such dividends as may be declared from time to time by the board from funds available therefor, (ii) no dividends may be declared, paid, or set aside for payment on shares of common stock unless full cumulative dividends are paid on any outstanding preference stock and any other preferred stock issued and outstanding at such time that is designated to have such dividend preference and (iii) upon dissolution the holders of shares of common stock are entitled to receive pro rata all assets of CVS Health available for distribution to such holders, subject to any liquidation preferences designated to any preferred stock or preference stock that may be issued and outstanding at such time of liquidation.

No Preemptive Rights
The Charter provides that no holder of any shares of CVS Health of any class or series may have any preemptive right to purchase or subscribe to any shares of CVS Health or any security convertible into shares of CVS Health of any class or series.

Provisions Relating to Amendments to CVS Health’s Charter and By-Laws
Under Delaware law, stockholders have the right to adopt, amend or repeal the certificate of incorporation and by-laws of a corporation. However, Delaware law requires that any amendment to the Charter also be approved by the board. Under Delaware law, unless a higher vote is required in a corporation’s certificate of incorporation, amendments to the corporation’s certificate of incorporation will be adopted upon receiving at a properly convened meeting the affirmative vote of a majority of the votes cast by all stockholders entitled to vote thereon, and if any class or series is entitled to vote thereon as a class, the affirmative vote of a majority of the votes cast in each class vote.

In addition, the By-Laws may be amended by the board with respect to all matters not exclusively reserved by law to the stockholders. Amendments to the By-Laws may be adopted and approved by the affirmative vote of the holders of record of a majority of the outstanding shares of stock of CVS Health entitled to vote at any annual or special meeting, or by the affirmative vote of a majority of the directors cast at any regular or special meeting, at which a quorum is present.

1

Certain Statutory and Charter Provisions
Certain provisions of the Charter and By-Laws summarized in the following paragraphs may be deemed to have an antitakeover effect and may delay, defer or prevent a tender offer or takeover attempt.  

Potential Issuances of Preferred Stock and Preference Stock
As of February 12, 2020, the Charter authorized 120,619 shares of preferred stock, par value $0.01 per share and 50,000,000 shares of preference stock, par value $1.00 per share. The Charter also authorizes the board to issue shares of preferred stock or preference stock, from time to time, in such class or classes, and such series within any class, and with such designations, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof as the board may determine, including, for example, (i) the designation of the class or series; (ii) the number of shares of the class or series, which number the board may thereafter (except where otherwise provided in the designation of any subsequently authorized class or series) increase or decrease (but not below the number of shares thereof then outstanding); (iii) whether dividends, if any, will be cumulative or noncumulative and the dividend rate of the class or series; (iv) the dates on which dividends, if any, will be payable; (v) the redemption rights and price or prices, if any, for shares of the class or series; (vi) the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the class or series; (vii) the amounts payable on shares of the class or series in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of CVS Health; (viii) whether the shares of the class or series will be convertible into shares of any other class or series, or any other security, of CVS Health or any other corporation, and, if so, the specification of such other class or series or such other security, the conversion price or prices or rate or rates, any adjustments thereof, the date or dates as of which such shares will be convertible and all other terms and conditions upon which such conversion may be made; (ix) restrictions on the issuance of shares of the same class or series or of any other class or series; and (x) the voting rights, if any, of the holders of such class or series. The authorized capital stock of CVS Health, including preferred stock, preference stock and common stock, will be available for issuance without further action by CVS Health stockholders, unless such action is required by applicable law or the rules of any stock exchange or automated quotation system on which CVS Health’s securities may be listed or traded. If the approval of CVS Health stockholders is not so required, the board does not intend to seek stockholder approval.
Although the board has no intention at the present time of doing so, it could issue a class or series of preferred stock or preference stock that could, depending on the terms of such class or series, impede completion of a merger, tender offer or other takeover attempt that the holders of some, or a majority, of CVS Health shares might believe to be in their best interests or in which CVS Health stockholders might receive a premium for their shares over the then-current market price of such shares.

Potential Issuances of Rights to Purchase Securities
CVS Health does not currently have a stockholder rights plan, although the board retains the right to adopt a new plan at a future date. The Charter grants the board exclusive authority to create and issue rights entitling the holders thereof to purchase from CVS Health shares of capital stock or other securities and to elect to repurchase, redeem, terminate or amend any such rights. The times at which and terms upon which such rights are to be issued, repurchased, redeemed, terminated or amended are to be determined exclusively by the board and set forth in the contracts or instruments that evidence any such rights. The authority of the board with respect to such rights includes determining, for example, (i) the purchase price of the capital stock or other securities or property to be purchased upon exercise of such rights; (ii) provisions relating to the times at which and the circumstances under which such rights may be exercised or sold or otherwise transferred, either together with or separately from any other shares or other securities of CVS Health; (iii) provisions which adjust the number or exercise price of such rights or the amount or nature of the shares, other securities or other property receivable upon exercise of such rights in the event of a combination, split or recapitalization of any shares of CVS Health, a change in ownership of CVS Health’s shares or other securities or a reorganization, merger, consolidation, sale of assets or other occurrence relating to CVS Health or any shares of CVS Health, and provisions restricting the ability of CVS Health to enter into any such transaction absent an assumption by the other party or parties thereto of the obligations of CVS Health under such rights; (iv) provisions which deny the holder of a specified percentage of the outstanding securities of CVS Health the right to exercise such rights and/or cause such rights held by such holder to become void; (v) provisions which

2

permit CVS Health to redeem or exchange such rights; and (vi) the appointment of the rights agent with respect to such rights. This provision is intended to confirm the board’s exclusive authority to issue, repurchase, redeem, terminate or amend share purchase rights or other rights to purchase shares or securities of CVS Health or any other corporation.

Stockholder Action by Written Consent
The Charter provides that stockholder action may be taken at an annual or special meeting of stockholders or by written consent in lieu of a meeting, but only if such action is taken in accordance with the provisions of the Charter and By-Laws. Any person other than CVS Health seeking to have the CVS Health stockholders authorize or take corporate action by written consent without a meeting is required to deliver a written notice signed by holders of record of at least twenty-five percent (25%) of the voting power of the outstanding capital stock of CVS Health entitled to express consent on the relevant action and request that a record date be fixed for such purpose.

Stockholder Vote on Fundamental or Extraordinary Corporate Transactions
Under Delaware law, a sale, lease or exchange of all or substantially all of CVS Health’s assets, an amendment to the Charter, a merger or consolidation of CVS Health with another corporation or a dissolution of CVS Health generally requires the affirmative vote of the board and, with limited exceptions, the affirmative vote of a majority of the aggregate voting power of the outstanding stock entitled to vote on the transaction.
With respect to transactions with related persons (persons who own at least 10% of the outstanding capital stock of CVS Health), the Charter provides that a majority of outstanding shares (excluding those owned by the related person) voting as a single class is required to approve a business combination transaction with a related person, unless (i) such transaction is approved by a majority of continuing directors (directors who are not the related person, or an affiliate or associate thereof (or a representative or nominee of the related person or such affiliate or associate), that is involved in the relevant business combination and (a) who were members of the board immediately prior to the time that such related person became a related person or (b) whose initial election as a director was recommended by the affirmative vote of a least a majority of the continuing directors then in office, provided that, in either such case, such continuing director has continued in office after becoming a continuing director) or (ii) certain fair price requirements are met.

State Anti-Takeover Provisions
CVS Health has not opted out of Section 203 of the Delaware General Corporation Law, which provides that, if a person acquires 15% or more of the outstanding voting stock of a Delaware corporation, thereby becoming an “interested stockholder,” that person may not engage in certain “business combinations” with the corporation, including mergers, purchases and sales of 10% or more of its assets, stock purchases and other transactions pursuant to which the percentage of the corporation’s stock owned by the interested stockholder increases (other than on a pro rata basis) or pursuant to which the interested stockholder receives a financial benefit from the corporation, for a period of three years after becoming an interested stockholder unless one of the following exceptions applies: (i) the board approved the acquisition of stock pursuant to which the person became an interested stockholder or the transaction that resulted in the person becoming an interested stockholder prior to the time that the person became an interested stockholder; (ii) upon consummation of the transaction that resulted in the person becoming an interested stockholder such person owned at least 85% of the outstanding voting stock of CVS Health, excluding, for purposes of determining the voting stock outstanding, voting stock owned by directors who are also officers and certain employee stock plans; or (iii) the transaction is approved by the board and by the affirmative vote of two-thirds of the outstanding voting stock which is not owned by the interested stockholder. An “interested stockholder” also includes the affiliates and associates of a 15% or more owner and any affiliate or associate of CVS Health who was the owner of 15% or more of the outstanding voting stock within the three-year period prior to determine whether a person is an interested stockholder.

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]